ArticleFrontiers in cardiovascular medicine2018
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
Article in Frontiers in cardiovascular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.Annals of the rheumatic diseases · 2021Guideline
- Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding.Journal of thrombosis and thrombolysis · 2026Review
- Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential.Biomedicines · 2025Review
- Article
- Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases.BMC neurology · 2025Article
- Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1.Scientific reports · 2024Article
- Cellular and Molecular Mechanisms of Mast Cells in Atherosclerotic Plaque Progression and Destabilization.Clinical reviews in allergy & immunology · 2024Review
- Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy.Frontiers in pharmacology · 2024Article
- Thrombosis in Myeloid Malignancies: From CHIP to AML.Cardiovascular & hematological disorders drug targets · 2024Review
- Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies.Cardiovascular toxicology · 2023Review
- Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation.Scientific reports · 2023Observational
- Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on VigibaseCancers · 2023Article
- Mechanism Research of Platelet Core Marker Prediction and Molecular Recognition in Cardiovascular Events.Combinatorial chemistry & high throughput screening · 2023Article
- The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.British journal of pharmacology · 2022Article
- Cardiometabolic Consequences of Targeted Anticancer Therapies.Journal of cardiovascular pharmacology · 2022Review
- An evaluation of the effects of Pistacia atlantica gum hydro-alcoholic extract on the phagocytosis ability of macrophages and atherosclerosis development in hypercholesteremic rats.ARYA atherosclerosis · 2022Article
- Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It.Journal of clinical medicine · 2022Review
- Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy.Journal of the advanced practitioner in oncology · 2022Review
- Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the vascular adverse effects of three generations of TKIs in a translational model for atherosclerosis, the APOE*3Leiden.CETP mouse. Mice were treated for sixteen weeks with imatinib (150 mg/kg BID), nilotinib (10 and 30 mg/kg QD) or ponatinib (3 and 10 mg/kg QD), giving similar drug exposures as in CML-patients. Cardiovascular risk factors were analyzed longitudinally, and histopathological analysis of atherosclerosis and transcriptome analysis of the liver was performed. Imatinib and ponatinib decreased plasma cholesterol (imatinib, -69%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.